Celltrion Chairman Seo Jung-jin has hinted that South Korea’s biosimilar power could explore vaccine development to ensure Korea’s sovereignty in cure and immunization strength versus novel coronavirus.

At an online press conference on Thursday, Seo said he is reviewing the possibility of entering vaccine development to reduce reliance on foreign vaccines.

The country already has a diagnosis system and treatment for Covid-19, but must rely on overseas drug makers when it comes to the vaccines, he said.

[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]